Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy.

Part 4 of this study is currently enrolling.
Multiple Myeloma
DRUG: Carfilzomib|DRUG: Venetoclax|DRUG: Dexamethasone
Number of Participants with Adverse Events, An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment., First dose of study drug through at least 30 days after end of treatment (approximately 2 years)|Very Good Partial Response (VGPR) or Better Response Rate of VenKd in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) as well as Those with t(11;14)-positive RRMM, VGPR or better response rate is defined as the percentage of participants with documented VGPR or better based on IMWG criteria., First dose of study drug through at least 30 days after end of treatment (approximately 2 years)|Objective Response Rate (ORR) of VenKd in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) as well as Those with t(11;14)-positive RRMM, ORR is defined as the percentage of participants with a documented PR or better based on IMWG criteria., First dose of study drug through at least 30 days after end of treatment (approximately 2 years)|Complete Response (CR) or Better Rate of VenKd in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) as well as Those with t(11;14)-positive RRMM, Complete response or better rate is defined as the percentage of participants with documented CR or better based on IMWG criteria., First dose of study drug through at least 30 days after end of treatment (approximately 2 years)
Very Good Partial Response (VGPR) or Better Response Rate in Participants with Relapsed or Refractory Multiple Myeloma and in a Subset of Participants with High B-cell lymphocyte-2 (BCL-2) Expression, VGPR or better response rate is defined as the proportion of participants with documented VGPR or better based on IMWG criteria., Up to approximately 17 months|Progression-free survival (PFS) in Participants with Relapsed or Refractory Multiple Myeloma and in a Subset of Participants with High B-cell lymphocyte-2 (BCL-2) Expression, PFS is defined as the number of days from the date of the first dose of study drug to the date of the first documented progressive disease (PD) or death due to any cause, whichever occurs first., Up to approximately 17 months|Minimal residual disease (MRD), MRD in the bone marrow by next generation sequencing., Up to 2 years (Screening, Cycle 3 Day 1, and Confirmation of Stringent Complete Response [sCR]/Complete Response [CR])|Duration of Overall Response (DOR) in Participants with Relapsed or Refractory Multiple Myeloma and in a Subset of Participants with High B-cell lymphocyte-2 (BCL-2) Expression, DOR is defined as the number of days from the participant's date of first documented response (PR or better) to the date of first documented PD or death due to MM, whichever occurs first., Up to approximately 17 months|Time to progression (TTP) in Participants with Relapsed or Refractory Multiple Myeloma and in a Subset of Participants with High B-cell lymphocyte-2 (BCL-2) Expression, TTP is defined as the number of days from the date of the first dose of study drug to the date of first documented PD or death due to MM, whichever occurs first., Up to approximately 17 months|Objective response rate (ORR) in Participants with Relapsed or Refractory Multiple Myeloma and in a Subset of Participants with High B-cell lymphocyte-2 (BCL-2) Expression, ORR is defined as the proportion of participants with documented partial response (PR) or better based on International Myeloma Working Group (IMWG) criteria., Up to approximately 17 months|Time to Response (TTR) in Participants with Relapsed or Refractory Multiple Myeloma and in a Subset of Participants with High B-cell lymphocyte-2 (BCL-2) Expression, TTR is defined as the number of days from the date of the first dose of study drug to the date of first documented response (Partial Response (PR) or better)., Up to approximately 17 months|Area under the plasma concentration-time curve from 0 to 24 hours (AUC0-24) post-dose of Venetoclax, AUC0-24 post-dose of venetoclax., Approximately 24 hours post-dose on Cycle 1 Days 1 and 15|Clearance (CL) of Carfilzomib, CL of carfilzomib., Approximately 4 hours post-dose on Cycle 1 Days 1 and 15|Terminal Phase Elimination Rate Constant (β) of Carfilzomib, β of carfilzomib., Approximately 4 hours post-dose on Cycle 1 Days 1 and 15|AUC from 0 to Infinity (AUC∞) of Carfilzomib, AUC∞ of carfilzomib., Approximately 4 hours post-dose on Cycle 1 Days 1 and 15|AUC from Time 0 to the Time of the Last Measurable Concentration (AUCt) of Carfilzomib, AUCt of carfilzomib., Approximately 4 hours post-dose on Cycle 1 Days 1 and 15|Maximum Plasma Concentration (Cmax) of Venetoclax, Cmax of venetoclax., Approximately 24 hours post-dose on Cycle 1 Days 1 and 15|Cmax of Carfilzomib, Cmax of carfilzomib., Approximately 4 hours post-dose on Cycle 1 Days 1 and 15|Terminal Elimination Half-life (t1/2) of Carfilzomib, t1/2 of carfilzomib., Approximately 4 hours post-dose on Cycle 1 Days 1 and 15|Time to Maximum Plasma Concentration (Peak Time, Tmax) of Venetoclax, (Peak time, Tmax) of venetoclax., Approximately 24 hours post-dose on Cycle 1 Days 1 and 15
A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy.

Part 4 of this study is currently enrolling.